A single infusion of an AAV-based gene therapy challenges decades of factor replacement in the management of severe haemophilia A.
Introduction
For half a century, treatment for haemophilia A has relied on intravenous replacement of factor VIII, this either comes from plasma derived sources or recombinant products. While these therapies reduce bleeding episodes, they demand lifelong adherence, carry risk of inhibitor development, and do not fully prevent joint damage or morbidity. Gene therapy represents a fundamental shift in strategy: instead of frequent exogenous infusions, it aims to reprogram the patient’s own cells to produce factor VIII endogenously, offering the possibility of long-term correction.
What is Roctavian?
Roctavian (valoctocogene roxaparvovec) is an AAV5-based gene therapy that delivers a B-domain deleted human factor VIII transgene to hepatocytes. After a single intravenous infusion, liver cells begin synthesizing functional factor VIII, restoring coagulation capacity. Unlike replacement therapy, this approach has the potential to provide sustained, physiologically regulated factor VIII production from within the body itself.
Breakthroughs in haemophilia A: Clinical trials
The pivotal GENEr8-1 phase 3 trial (NEJM, 2022) enrolled adult patients with severe haemophilia A who were on prophylactic factor VIII therapy.
The outcomes of this trial found:
- Annualised bleeding rate (ABR): A reduction of 84% compared with baseline.
- Factor VIII use: Most participants were able to discontinue prophylaxis entirely, with over 95% showing marked reductions in factor concentrate usage.
- Sustained expression: Median follow-up of three years demonstrated persistence of factor VIII expression, though with gradual decline over time.
- Safety profile: The most common adverse events were elevated liver transaminases, managed with corticosteroids. Importantly, there were no cases of insertional mutagenesis or vector-related oncogenesis.
These findings established Roctavian as the first gene therapy for haemophilia A to receive regulatory approval (EMA 2022, FDA 2023).
Considerations in regards to Roctavian
The benefits of Roctavian are clear: it can dramatically reduce bleeding episodes, free patients from burdensome prophylaxis, and improve quality of life. However, important limitations remain. Factor VIII expression decreases over time in many patients, raising questions about durability, pre-existing antibodies against AAV5 exclude a proportion of patients from eligibility, hepatotoxicity requires close monitoring and steroid use, which itself carries risks, and finally, the cost of over $2 million per infusion creates significant barriers to equitable global access.
Roctavian’s approval represents more than just a new drug, it validates the principle of gene therapy for complex clotting disorders. The therapy demonstrates that durable expression of a large, complex protein such as factor VIII is achievable. Yet the challenges highlight that this is not a cure in the absolute sense. The need for long term monitoring, the potential requirement for future re-dosing with alternative vectors, and uncertainties regarding lifetime durability mean that haemophilia A management will remain dynamic. Importantly, access issues will be critical, the majority of patients with haemophilia worldwide live in low and middle income countries, where even standard factor therapy is scarce.
Conclusion
Roctavian is a milestone in hemophilia A therapy, marking the transition from replacement medicine to genetic reprogramming. Its ability to significantly reduce bleeding risk and decrease dependence on prophylaxis demonstrates the power of gene therapy in altering disease trajectories. However, questions of durability, safety, and accessibility must be addressed before this innovation can be integrated broadly into clinical practice.